Regulatory Pressure Mounts for Telehealth Firm Hims & Hers Following FDA Warning
Published on 09/25/2025 at 12:18 | Redaktion boerse-global.de
The telehealth sector faces renewed scrutiny as Hims & Hers Health finds itself in the crosshairs of US regulators. A formal warning letter from the Food and Drug Administration (FDA), issued on September 9, has cast a shadow over the company’s advertising practices for its weight-loss medications, sending its shares lower and prompting market analysts to reassess their outlook.
At the heart of the regulatory action are assertions made by Hims & Hers regarding its compounded semaglutide products. The FDA’s letter charges the company with making “false and misleading” claims by suggesting these offerings contain “the same active ingredient as Ozempic and Wegovy” and utilize “clinically proven ingredients.”
The agency delivered an unambiguous message: compounded medications lack... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
